Saira Saeed Mirza1, Renée F A G de Bruijn2, Peter J Koudstaal3, Anton H van den Meiracker4, Oscar H Franco1, Albert Hofman1, Henning Tiemeier5, M Arfan Ikram6. 1. Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands. 2. Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands. 3. Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands. 4. Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands. 5. Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands Department of Department of Child and Adolescent Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands Department of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands. 6. Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands Department of Radiology, Erasmus Medical Center, Rotterdam, The Netherlands.
Abstract
BACKGROUND: The N-terminal pro B-type natriuretic peptide (NT-proBNP) has a well-documented prognostic value for cardiovascular disease (CVD) and higher levels are associated with cognitive-dysfunction in patients with CVD. However, how NT-proBNP relates to incident dementia and cognitive-decline in community-dwelling persons is unknown. METHODS: Between 1997 and 2001, serum NT-proBNP was measured in 6040 participants (mean age 69 years, 57% women) free of heart-failure and dementia from the Rotterdam Study. Participants were continuously followed-up for incident dementia until 2012, for 56,616 person-years. Cognition was assessed at baseline and reassessed between 2002 and 2006 by Letter-Digit-Substitution-task, Stroop test and Word-Fluency test. Associations of NT-proBNP with dementia (555 cases), Alzheimer's disease (357 cases) and vascular dementia (32 cases) were assessed linearly, and in quartiles using Cox regression. Associations of NT-proBNP with cognitive-decline were assessed using multiple linear regression. All analyses were repeated after excluding patients with CVD. RESULTS: Higher NT-proBNP was associated with a higher risk of dementia, even after excluding patients with CVD and adjusting for cardiovascular risk factors, HR per SD 1.27 (95% CI 1.13 to 1.44). Associations were particularly strong for vascular dementia, HR per SD 2.04 (95% CI 1.18 to 3.55), but also for Alzheimer's disease when comparing the second and third quartile with first. Higher NT-proBNP was cross-sectionally associated with poorer performance in multiple cognitive tests but longitudinally only in Letter-Digit-Substitution-task. CONCLUSIONS: NT-proBNP reflecting subclinical CVD is associated with dementia, particularly vascular dementia. NT-proBNP can be a useful marker of imminent cognitive-decline and dementia in absence of clinical CVD. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
BACKGROUND: The N-terminal pro B-type natriuretic peptide (NT-proBNP) has a well-documented prognostic value for cardiovascular disease (CVD) and higher levels are associated with cognitive-dysfunction in patients with CVD. However, how NT-proBNP relates to incident dementia and cognitive-decline in community-dwelling persons is unknown. METHODS: Between 1997 and 2001, serum NT-proBNP was measured in 6040 participants (mean age 69 years, 57% women) free of heart-failure and dementia from the Rotterdam Study. Participants were continuously followed-up for incident dementia until 2012, for 56,616 person-years. Cognition was assessed at baseline and reassessed between 2002 and 2006 by Letter-Digit-Substitution-task, Stroop test and Word-Fluency test. Associations of NT-proBNP with dementia (555 cases), Alzheimer's disease (357 cases) and vascular dementia (32 cases) were assessed linearly, and in quartiles using Cox regression. Associations of NT-proBNP with cognitive-decline were assessed using multiple linear regression. All analyses were repeated after excluding patients with CVD. RESULTS: Higher NT-proBNP was associated with a higher risk of dementia, even after excluding patients with CVD and adjusting for cardiovascular risk factors, HR per SD 1.27 (95% CI 1.13 to 1.44). Associations were particularly strong for vascular dementia, HR per SD 2.04 (95% CI 1.18 to 3.55), but also for Alzheimer's disease when comparing the second and third quartile with first. Higher NT-proBNP was cross-sectionally associated with poorer performance in multiple cognitive tests but longitudinally only in Letter-Digit-Substitution-task. CONCLUSIONS: NT-proBNP reflecting subclinical CVD is associated with dementia, particularly vascular dementia. NT-proBNP can be a useful marker of imminent cognitive-decline and dementia in absence of clinical CVD. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Yashashwi Pokharel; Farah Mouhanna; Andrea L C Schneider; Andreea M Rawlings; David S Knopman; Vijay Nambi; Salim S Virani; Ron C Hoogeveen; Alvaro Alonso; Gerardo Heiss; Josef Coresh; Thomas Mosley; Rebecca Gottesman; Elizabeth Selvin; Christie Ballantyne; Melinda C Power Journal: J Am Geriatr Soc Date: 2019-07-30 Impact factor: 5.562
Authors: Juho Tynkkynen; Jussi A Hernesniemi; Tiina Laatikainen; Aki S Havulinna; Perttu Salo; Stefan Blankenberg; Tanja Zeller; Veikko Salomaa Journal: J Neurol Date: 2016-12-30 Impact factor: 4.849
Authors: Lucy S Witt; Jason Rotter; Sally C Stearns; Rebecca F Gottesman; Anna M Kucharska-Newton; A Richey Sharrett; Lisa M Wruck; Jan Bressler; Carla A Sueta; Patricia P Chang Journal: J Gen Intern Med Date: 2018-07-20 Impact factor: 5.128
Authors: Mohammad R Ostovaneh; Kasra Moazzami; Kihei Yoneyama; Bharath A Venkatesh; Susan R Heckbert; Colin O Wu; Steven Shea; Wendy S Post; Annette L Fitzpatrick; Gregory L Burke; Hossein Bahrami; Otto A Sanchez; Lori B Daniels; Erin D Michos; David A Bluemke; João A C Lima Journal: Hypertension Date: 2019-12-23 Impact factor: 10.190
Authors: Lewis H Kuller; Oscar L Lopez; John S Gottdiener; Dalane W Kitzman; James T Becker; Yuefang Chang; Anne B Newman Journal: J Am Heart Assoc Date: 2017-07-22 Impact factor: 5.501
Authors: A Wallin; E Kapaki; M Boban; S Engelborghs; D M Hermann; B Huisa; M Jonsson; M G Kramberger; L Lossi; B Malojcic; S Mehrabian; A Merighi; E B Mukaetova-Ladinska; G P Paraskevas; B O Popescu; R Ravid; L Traykov; G Tsivgoulis; G Weinstein; A Korczyn; M Bjerke; G Rosenberg Journal: BMC Neurol Date: 2017-05-23 Impact factor: 2.474
Authors: Ian T Ferguson; Martine Elbejjani; Behnam Sabayan; David R Jacobs; Osorio Meirelles; Otto A Sanchez; Russell Tracy; Nick Bryan; Lenore J Launer Journal: Front Neurol Date: 2018-05-07 Impact factor: 4.003